Revenue + Forward P/E
Alnylam Pharmaceuticals, Inc. (ALNY) quarterly revenue and forward P/EForward P/E: 26.0x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$30.31B
Enterprise value
$35.85B
P/E ratio (TTM)
62.33x
P/S ratio (TTM)
8.46x
P/B ratio
33.58x
EV/Sales
8.36x
EV/EBITDA
38.78x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$3.71B
Gross profit (TTM)
$3.04B
Operating income (TTM)
$501.58M
EBITDA (TTM)
$631.44M
Net income (TTM)
$313.75M
Free cash flow (TTM)
$465.38M
Margins & returns
Gross margin
80.89%
Operating margin
17.54%
Profit margin
13.46%
Return on equity
98.29%
Return on assets
11.25%
Per-share metrics
EPS (TTM)
$4.34
Dividend yield
0.00%
Beta
0.27
Capital structure
Cash & equivalents
$1.66B
Total debt
$1.28B
Net debt
$-378.86M
Shares outstanding
133.81M
Financial health
Current ratio
2.76
Debt / equity
1.62
Debt / assets
0.26
Interest coverage
1.99
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $630.14B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $443.33B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $365.40B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $354.73B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $332.49B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $30.31B | 62.33x | 8.46x | 38.78x | - |